Antimicrobial peptide DP7 alleviates dextran sulfate sodium (DSS)‐induced colitis via modifying gut microbiota and regulating intestinal barrier function DOI Creative Commons
Binyan Zhao, Hongyou Zhou, Ke Lin

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(2)

Published: Jan. 30, 2025

Inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC), represent a growing global health concern. Restoring the balance of gut microbiota, crucial factor in intestinal health, offers potential for treating IBD. DP7, novel antimicrobial peptide with potent antibacterial activity, was investigated its anti-inflammatory effects dextran sulfate sodium (DSS)-induced UC mouse model. DP7 significantly ameliorated key parameters, including activity index, weight loss, shortened colon length, while preserving colonic epithelial integrity reducing inflammatory infiltration. Further analysis revealed targets highlighting significant role Muribaculaceae bacteria during states. To further explore microbiota DP7's efficacy, fecal transplantation (FMT) performed using feces from DP7-treated mice. FMT successfully recipient mice, providing evidence microbiome IBD treatment ability to modulate therapeutic benefit. Moreover, our findings suggest that modulation immune system is intricately linked complex microbial environment. Our demonstrate effectively mitigates inflammation, attenuates barrier dysfunction, shapes suggesting agent UC.

Language: Английский

Desulfovibrio vulgaris interacts with novel gut epithelial immune receptor LRRC19 and exacerbates colitis DOI Creative Commons

Runxiang Xie,

Yu Gu, Mengfan Li

et al.

Microbiome, Journal Year: 2024, Volume and Issue: 12(1)

Published: Jan. 3, 2024

The overgrowth of Desulfovibrio, an inflammation promoting flagellated bacteria, has been found in ulcerative colitis (UC) patients. However, the molecular mechanism remains unestablished. relative abundance Desulfovibrio vulgaris (D. vulgaris) stool samples UC patients was detected. Mice were treated with dextran sulfate sodium to induce or without administration D. flagellin (DVF), and severity leucine-rich repeat containing 19 (LRRC19) signaling assessed. interaction between DVF LRRC19 identified by surface plasmon resonance intestinal organoid culture. Lrrc19-/- Tlr5-/- mice used investigate indispensable role LRRC19. Finally, blockade DVF-LRRC19 selected through virtual screening efficacy enriched fecal correlated disease severity. treatment significantly exacerbated germ-free conventional mice. Mechanistically, could interact (rather than TLR5) organoids, then production pro-inflammatory cytokines. Lrrc19 knockdown blunted colitis. Furthermore, typhaneoside, a binding interfaces, blocked dramatically ameliorated DVF-induced promote interaction. Targeting might be new therapeutic strategy for therapy. Video Abstract.

Language: Английский

Citations

20
Mitochondrial function and gastrointestinal diseases DOI

Parsa Haque,

Neeraj Kapur,

Terrence A. Barrett

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 21(8), P. 537 - 555

Published: May 13, 2024

Language: Английский

Citations

20
Indole-3-acetic acid alleviates DSS-induced colitis by promoting the production of R-equol from Bifidobacterium pseudolongum DOI Creative Commons
Miaomiao Li, Xue Han, Lijun Sun

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: March 25, 2024

Background Inflammatory bowel disease (IBD) is characterized by immune-mediated, chronic inflammation of the intestinal tract. The occurrence IBD driven complex interactions multiple factors. objective this study was to evaluate therapeutic effects IAA in colitis.

Language: Английский

Citations

17
Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities DOI
Iliyan D. Iliev, Ashwin N. Ananthakrishnan, Chun‐Jun Guo

et al.

Nature Reviews Microbiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Language: Английский

Citations

3
Antimicrobial peptide DP7 alleviates dextran sulfate sodium (DSS)‐induced colitis via modifying gut microbiota and regulating intestinal barrier function DOI Creative Commons
Binyan Zhao, Hongyou Zhou, Ke Lin

et al.

MedComm, Journal Year: 2025, Volume and Issue: 6(2)

Published: Jan. 30, 2025

Inflammatory bowel diseases (IBDs), such as Crohn's disease (CD) and ulcerative colitis (UC), represent a growing global health concern. Restoring the balance of gut microbiota, crucial factor in intestinal health, offers potential for treating IBD. DP7, novel antimicrobial peptide with potent antibacterial activity, was investigated its anti-inflammatory effects dextran sulfate sodium (DSS)-induced UC mouse model. DP7 significantly ameliorated key parameters, including activity index, weight loss, shortened colon length, while preserving colonic epithelial integrity reducing inflammatory infiltration. Further analysis revealed targets highlighting significant role Muribaculaceae bacteria during states. To further explore microbiota DP7's efficacy, fecal transplantation (FMT) performed using feces from DP7-treated mice. FMT successfully recipient mice, providing evidence microbiome IBD treatment ability to modulate therapeutic benefit. Moreover, our findings suggest that modulation immune system is intricately linked complex microbial environment. Our demonstrate effectively mitigates inflammation, attenuates barrier dysfunction, shapes suggesting agent UC.

Language: Английский

Citations

2